NanoViricides Inc. (NNVC)

[Raffis]

NNVC Update on Pan-COVID-19 Drug Development
Highlights of the Presentation:

TWO Drug Candidates, NV-CoV-2 and NV-CoV-2-R in Development to Enter Clinical Trials
Both Possess Broad-Spectrum Activities Against Many Coronaviruses
Both Are Thus Expected to Continue to Work Against Variants
Even as SARS-CoV-2 Continues to Evolve with Increasing Resistance to Existing Drugs and Antibodies
Variants Would Therefore Not be Able to Escape Our Drugs, Particularly NV-CoV-2-R
Novel Mechanism of Action, Unlike Existing Drugs
NV-CoV-2-R is the Only Drug in Development with a Dual Mode of Action
Block Virus from Attacking Cells in the first place, and
Inhibit Virus Replication Inside Cells, Simultaneously
NV-CoV-2-R is the Only Drug in Development that Blocks the Complete Lifecycle of the Virus
NV-CoV-2 Component Neutralizes Virus Outside Cells Blocking Reinfection Cycle
Remdesivir Component Blocks the Replication Cycle Inside Cells
Makes it very difficult for virus to escape the drug
Animal Model Studies Have Indicated that Both NV-CoV-2 and NV-CoV-2-R are Substantially Superior to Remdesivir in Controlling Coronavirus Lethal Lung Infection
Lifespan Extension Over Untreated Infected Animals:
Remdesivir: 2.5 days (Only 50% Increase)
NV-CoV-2: 14 days (180% Increase)
NV-CoV-2-R: 16 days (220% Increase).
Both NV-CoV-2 and NV-CoV-2-R are Extremely Safe
NV-CoV-2 Well Tolerated at >3.3 g/kg Body Weight in Rats by I.V. Infusion
NV-CoV-2-R Well Tolerated at >1.8 g/kg Body Weight in Rats by I.V. Infusion
Anticipate Substantial Therapeutic Margin of Safety in Clinical Studies
Required GLP Safety/Toxicology Studies of NV-CoV-2 Completed
No Respiratory or Neurological Function Adverse Effects in a GLP Rat Neuro-Pulmonary Model Studies
No Cardiovascular Function Adverse Effects in a GLP Study in Cynomolgus Monkey (Non-Human Primate) Model
"Importantly, NV-CoV-2 can be administered orally, and was found to be effective given orally in an animal model," Dr. Diwan added, "Oral NV-CoV-2 should enable highly effective treatments for pediatric use, an urgent medical need that remains unmet with even the most talked about current drug developments".